Advertisement
![Picture [iito] Made Without Love 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-made-without-love.jpg)
Organisation › Details
Ysios Capital Partners SGECR S.A.
Ysios Capital is a leading Spanish venture capital firm that provides private equity financing to early- and mid-stage, highly innovative life science companies bringing life-changing treatments to patients, with a focus on indications with high unmet need. Our diverse international team in San Sebastián and Barcelona is driven by science, with the ambition to transform capital into medical breakthroughs. Ysios Capital was founded in 2008 and has over $450 million in assets under management through its three funds. *
![]() |
Start | 2008-01-01 established |
Group | Ysios Capital (Group) | |
![]() |
Industry | venture capital |
Industry 2 | LIFE SCIENCES | |
![]() |
Person | Casellas, Marc (SOM Biotech 202106– CFO before Ysios Capital Partners + Danone Group + PwC Consulting) |
Person 2 | Jean-Mairet, Joël (Ysios Capital 201206) | |
![]() |
Region | Barcelona |
Country | Spain (España) | |
Street | 11 Travessera de Gràcia 8th Floor | |
City | 08021 Barcelona | |
Tel | +34-93-517-3545 | |
Address record changed: 2021-04-28 | ||
Basic data | Employees | B: 11 to 50 (2015-08-18) |
Currency | EUR | |
Annual sales | 450,000,000 (assets, managed (2022) 2022-03-04) | |
* Document for �About Section�: Ysios Capital. (3/4/22). "Press Release: Ysios Capital Strengthens Its Team with the Appointment of Thomas Harth as Principal Thomas Harth". San Sebastián & Barcelona. | ||
Record changed: 2022-10-10 |
Advertisement
![Picture [iito] [LSE] Life-Sciences-Europe.com Business Portal 650x200px](/banner/iito-business-intelligence-20220406-650-200-lse-life-sciences-europe.jpg)
More documents for Ysios Capital (Group)
- [1] SparingVision S.A.S.. (9/14/22). "Press Release: SparingVision Raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines for Ocular Diseases"....
- [2] NorthSea Therapeutics B.V.. (12/17/21). "Press Release: NorthSea Therapeutics Completes US$80 Million Series C Fundraising to Advance Clinical Programs in Metabolic Disorders". Amsterdam....
- [3] Galecto Biotech AB. (10/26/18). "Press Release: Galecto Biotech Raises €79 Million in Series C Financing Co-Led by Ysios Capital and OrbiMed to Advance Galectin Inhibitor to Late-Stage Clinical Development". Copenhagen....
- [4] Ysios Capital. (9/24/18). "Press Release: Ysios Capital Strengthens Its Team with the Appointment of Guillem Laporta as Principal and Two New Venture Partners". Barcelona....
- [5] Xeltis AG. (11/15/17). "Press Release: Xeltis Closes €45 Million in Oversubscribed Series C Financing to Advance Aortic and Pulmonary Valve Programs". Zurich & Eindhoven....
- [6] BioClin Therapeutics, Inc.. (3/22/17). "Press Release: BioClin Therapeutics, Inc., Raises $30 Million in Series B Financing Led by Sofinnova Ventures and Ysios Capital". San Ramon, CA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
![Picture [iito] [LSE] Life-Sciences-Europe.com Business Portal 650x300px](/banner/iito-business-intelligence-20220406-650-300-lse-life-sciences-europe.jpg)
» top